Catalent to Invest $10 Million to Expand High Potency Containment Capabilities For Micronization
Catalent, the leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell and
gene therapies, and consumer health products, today announced that it
is investing $10 million in isolator capabilities at its sites in
Malvern, Pennsylvania and Dartford, U.K., to expand its micronization
capabilities for highly potent drug compounds.
More info >> |